Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting
May 01 2023 - 4:00AM
Vivoryon Therapeutics N.V. Announces Planned Changes to Board
Composition at 2023 Annual General Meeting
Vivoryon Therapeutics
N.V. Announces Planned Changes
to Board Composition at
2023 Annual General Meeting
Halle (Saale) / Munich,
Germany, May 1,
2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam:
VVY; NL00150002Q7) (Vivoryon), a clinical stage
company focused on the discovery and development of small molecule
medicines to modulate the activity and stability of pathologically
altered proteins, today announced intended changes among the
Non-Executive members of its Board of Directors at Vivoryon’s 2023
Annual General Meeting to be held later this year.
Reflecting Vivoryon’s continued progress towards
becoming a late-stage clinical development company and in line with
the Company’s commitment to meeting international best-practice
standards for corporate governance and diversity, the two
long-standing members Dinnies Johannes von der Osten, PhD, and
Jörg Neermann, PhD, have decided in agreement with the Company to
step down at the 2023 Annual General Meeting. Vivoryon intends to
propose the appointment of one or two new Non-Executive Board
members, with the objective of the Board’s composition better
reflecting the Company’s current shareholder structure and
strategic growth opportunities.
“On behalf of the Board of Directors and the
entire Vivoryon team, I would like to thank Dinnies von der
Osten and Jörg Neermann for their valuable contributions over the
years,” said Erich Platzer, MD, Chairman of the Board of Directors
of Vivoryon. “In over a decade of service, they helped to guide the
Company through many stages of development. I sincerely wish them
all the best in their future endeavors. I look forward to providing
an update on the proposed Board additions in the context of our
AGM.”
The full agenda for the 2023 Annual General
Meeting will be published on Vivoryon’s website in May 2023.
###
About Vivoryon Therapeutics
N.V.Vivoryon is a clinical stage biotechnology company
focused on developing innovative small molecule-based medicines.
Driven by our passion for ground-breaking science and innovation,
we strive to change the lives of patients in need suffering from
severe diseases. We leverage our in-depth expertise in
understanding post-translational modifications to develop medicines
that modulate the activity and stability of proteins which are
altered in disease settings. Beyond our lead program,
varoglutamstat, which is in Phase 2 clinical development to treat
Alzheimer’s disease, we have established a solid pipeline of
orally available small molecule inhibitors for various indications
including cancer, inflammatory diseases and fibrosis.
www.vivoryon.com
Vivoryon Forward Looking
StatementsThis press release includes forward-looking
statements, including, without limitation, those regarding the
business strategy, management plans and objectives for future
operations of the Vivoryon Therapeutics N.V. (the “Company”),
estimates and projections with respect to the market for the
Company’s products and forecasts and statements as to when the
Company’s products may be available. Words such as “anticipate,”
“believe,” “estimate,” “expect,” “forecast,” “intend,” “may,”
“plan,” “project,” “predict,” “should” and “will” and similar
expressions as they relate to the Company are intended to identify
such forward-looking statements. These forward-looking statements
are not guarantees of future performance; rather they are based on
the Management’s current expectations and assumptions about future
events and trends, the economy and other future conditions. The
forward-looking statements involve a number of known and unknown
risks and uncertainties. These risks and uncertainties and other
factors could materially adversely affect the outcome and financial
effects of the plans and events described herein. Actual results,
performance or events may differ materially from those expressed or
implied in such forward-looking statements and from expectations.
As a result, no undue reliance should be placed on such
forward-looking statements. This press release does not contain
risk factors. Certain risk factors that may affect the Company’s
future financial results are discussed in the published annual
financial statements of the Company. This press release, including
any forward-looking statements, speaks only as of the date of this
press release. The Company does not assume any obligation to update
any information or forward-looking statements contained herein,
save for any information required to be disclosed by law.
For more information, please contact:
Investor ContactStern IRJulie SeidelTel: +1
212-698-8684Email: SternIR-Vivoryon@sternir.com
Media ContactTrophic CommunicationsValeria
FisherTel: +49 175 8041816Email: vivoryon@trophic.eu
- 20230501_AGM Announcement_final
Vivoryon Therapeut (EU:VVY)
Historical Stock Chart
From Apr 2024 to May 2024
Vivoryon Therapeut (EU:VVY)
Historical Stock Chart
From May 2023 to May 2024